On Tuesday, Shares of Fastenal Company (NASDAQ:FAST), subtract -0.02% and closed at $45.09 in the last trading session. The last trading range of the stock ranges between $44.39 and $45.43. The company’s Market capitalization is $13.27 Billion with the total Outstanding Shares of 289.03 million. During the 52-week trading session the minimum price at which share price traded, registered at $35.10 and reached to max level of $49.99. The EPS of company is strolling at 1.72. Fastenal Company, together with its auxiliaries, engages in the wholesale distribution of industrial and construction supplies in the United States, Canada, and internationally. It offers fasteners, and other industrial and construction supplies mainly under the Fastenal name. The companys fastener products include threaded fasteners, such as bolts, nuts, screws, studs, and related washers, which are used in manufactured products and building projects, in addition to in the maintenance and repair of machines and structures. It also offers miscellaneous supplies and hardware, counting various pins and machinery keys, concrete anchors, metal framing systems, wire ropes, strut products, rivets, and related accessories. The company serves the manufacturing market comprising original equipment manufacturers, maintenance, repair, and operations; and non-residential construction market, which include general, electrical, plumbing, sheet metal, and road contractors.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), dropped -2.03% and closed at $28.47 in the last trading session. The last trading range of the stock ranges between $27.60 and $29.27. The company’s Market capitalization is $3.48 Billion with the total Outstanding Shares of 121.11 million. During the 52-week trading session the minimum price at which share price traded, registered at $16.64 and reached to max level of $42.49. The EPS of company is strolling at -2.14. ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, recently declared the initiation of ADVANCE, a Phase II study to evaluate pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia. Studies show that about 40 to 50 percent of schizophrenia patients suffer from prominent negative symptoms. There is presently no drug approved by the U.S. Food and Drug Administration for the treatment of these negative symptoms. As a selective serotonin inverse agonist (SSIA), pimavanserin is a new class of antipsychotic medication with a distinct mechanism of action targeting serotonergic 5-HT2A receptors while avoiding activity at dopamine and other receptors commonly targeted by other antipsychotics.
“Presently available treatments do not adequately address negative symptoms of schizophrenia, which are highly prevalent and contribute significantly to the long term disability and functional impairment of people with this disease,” said Serge Stankovic, M.D., M.S.P.H., ACADIA’s Executive Vice President, Head of Research and Development. “With its highly selective pharmacological profile, we believe pimavanserin may address this unmet need and improve clinical outcomes for these patients.”